<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">J Res Med Sci</journal-id><journal-id journal-id-type="iso-abbrev">J Res Med Sci</journal-id><journal-id journal-id-type="publisher-id">JRMS</journal-id><journal-title-group><journal-title>Journal of Research in Medical Sciences : The Official Journal of Isfahan University of Medical Sciences</journal-title></journal-title-group><issn pub-type="ppub">1735-1995</issn><issn pub-type="epub">1735-7136</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25002886</article-id><article-id pub-id-type="pmc">4078386</article-id><article-id pub-id-type="publisher-id">JRMS-19-1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Statin efficacy in the treatment of hepatitis C genotype I</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shavakhi</surname><given-names>Ahmad</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Minakari</surname><given-names>Mohamad</given-names></name><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Bighamian</surname><given-names>Afshin</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Sadeghian</surname><given-names>Sina</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Shavakhi</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="aff2">1</xref></contrib><contrib contrib-type="author"><name><surname>Khamisi</surname><given-names>Naser</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Khodadustan</surname><given-names>Mahsa</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Talebi</surname><given-names>Majid</given-names></name><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Ataei</surname><given-names>Behrooz</given-names></name><xref ref-type="aff" rid="aff3">2</xref></contrib></contrib-group><aff id="aff1">Department of Gastroenterology and Hepatology, Isfahan University of Medical Sciences, Isfahan, Iran</aff><aff id="aff2"><label>1</label>Department of Gastroenterology and Hepatology, Shahrekord University of Medical Sciences, Isfahan, Iran</aff><aff id="aff3"><label>2</label>Infectious Diseases and Tropical Medicine Research Center, Isfahan University of Medical Sciences, Isfahan, Iran</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Mohamad Minakari, Department of Gastroenterology and Hepatology, Isfahan University of Medical Sciences, Isfahan, Iran. E-mail: <email xlink:href="minakari@med.mui.ac.ir">minakari@med.mui.ac.ir</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2014</year></pub-date><volume>19</volume><issue>Suppl 1</issue><fpage>S1</fpage><lpage>S4</lpage><history><date date-type="received"><day>18</day><month>1</month><year>2014</year></date><date date-type="rev-recd"><day>05</day><month>2</month><year>2014</year></date><date date-type="accepted"><day>02</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>Copyright: © Journal of Research in Medical Sciences</copyright-statement><copyright-year>2014</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="4306" xml_f="4317" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="4328" xml_f="4620" txt_i="23" txt_f="315">Lipid metabolism is one of the hepatitis C virus (HCV) life cycle steps. Statins can reduce cholesterol level and finally can decrease HCV replication. Thus, we assessed the effect of Statins in combination with standard antiviral treatment on hyperlipidemic genotype I HCV infected patients.</offsets></p></sec><sec id="st2"><title><offsets xml_i="4651" xml_f="4673" txt_i="317" txt_f="339">Materials and Methods:</offsets></title><p><offsets xml_i="4684" xml_f="5313" txt_i="340" txt_f="969">This study was a prospective clinical trial. 40 patients were selected from those referred to educational and Therapeutic Centers of Isfahan University of Medical Sciences from 2009 to 2010 with confirmed HCV viremia. All patients received Peg-interferon-a2a and ribavirin. 20 hyperlipidemic Patients received 20 mg atorvastatin nightly for 3 months and placebo was prescribed for 20 normolipidemic HCV infected patients as a control group. Liver enzymes and complete blood count were checked monthly and thyroid stimulating hormone was checked every 3 months. We also performed quantitative HCV-ribonucleic acid (RNA) test in 12</offsets><sup><offsets xml_i="5318" xml_f="5320" txt_i="969" txt_f="971">th</offsets></sup><offsets xml_i="5326" xml_f="5411" txt_i="971" txt_f="1056"> week of therapy, at the end of treatment and 6 months after therapy for all samples.</offsets></p></sec><sec id="st3"><title><offsets xml_i="5442" xml_f="5450" txt_i="1058" txt_f="1066">Results:</offsets></title><p><offsets xml_i="5461" xml_f="5574" txt_i="1067" txt_f="1180">We didn’t find any significant differences in the mean of HCV-RNA numbers between statin and placebo groups in 12</offsets><sup><offsets xml_i="5579" xml_f="5581" txt_i="1180" txt_f="1182">th</offsets></sup><offsets xml_i="5587" xml_f="5661" txt_i="1182" txt_f="1256"> week of treatment, in the end of treatment and 6 months after treatment (</offsets><italic><offsets xml_i="5669" xml_f="5670" txt_i="1256" txt_f="1257">P</offsets></italic><offsets xml_i="5679" xml_f="5691" txt_i="1257" txt_f="1266"> &gt; 0.05).</offsets></p></sec><sec id="st4"><title><offsets xml_i="5722" xml_f="5733" txt_i="1268" txt_f="1279">Conclusion:</offsets></title><p><offsets xml_i="5744" xml_f="6014" txt_i="1280" txt_f="1550">Atorvastatin has no effect on the mean of HCV viral load when we added it to standard treatment for hepatitis C infection. Further studies are necessary to examine the possible antiviral properties of statins and their potential role as adjuncts to standard HCV therapy.</offsets></p></sec></abstract><kwd-group><kwd>Hepatitis C</kwd><kwd>hyperlipidemia</kwd><kwd>statins</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="6193" xml_f="6205" txt_i="1559" txt_f="1571">INTRODUCTION</offsets></title><p><offsets xml_i="6216" xml_f="6643" txt_i="1572" txt_f="1999">Hepatitis C virus (HCV) is an important human pathogen, not only because of its high prevalence and worldwide burden, but also because of the potentially serious complications of persistent HCV infection. These complications include cirrhosis, hepatocellular carcinoma, and end-stage liver disease necessitating liver transplantation. The incidence rates for all of these complications are expected to rise in the near future.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="6676" xml_f="6677" txt_i="1999" txt_f="2000">1</offsets></xref><xref rid="ref2" ref-type="bibr"><offsets xml_i="6717" xml_f="6718" txt_i="2000" txt_f="2001">2</offsets></xref><offsets xml_i="6725" xml_f="6726" txt_i="2001" txt_f="2002">]</offsets></p><p><offsets xml_i="6733" xml_f="6830" txt_i="2003" txt_f="2100">It is estimated that 130-170 million people have chronic HCV (about 3% of the world population).[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="6863" xml_f="6864" txt_i="2100" txt_f="2101">3</offsets></xref><xref rid="ref4" ref-type="bibr"><offsets xml_i="6904" xml_f="6905" txt_i="2101" txt_f="2102">4</offsets></xref><offsets xml_i="6912" xml_f="6996" txt_i="2102" txt_f="2186">] More than 3,00,000 people die every year from hepatitis C related liver diseases.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="7029" xml_f="7030" txt_i="2186" txt_f="2187">5</offsets></xref><offsets xml_i="7037" xml_f="7107" txt_i="2187" txt_f="2257">] There is no vaccination for HCV, so the treatment is very important.</offsets></p><p><offsets xml_i="7114" xml_f="7293" txt_i="2258" txt_f="2437">The standard medication of HCV (pegylated interferon (IFN) alpha plus ribavirin [RBV]) in HCV genotype I infected patients have shown 40-50% sustained virological response (SVR),[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="7326" xml_f="7327" txt_i="2437" txt_f="2438">3</offsets></xref><offsets xml_i="7334" xml_f="7379" txt_i="2438" txt_f="2483">] so we need more effective treatment method.</offsets></p><p><offsets xml_i="7386" xml_f="7541" txt_i="2484" txt_f="2639">Lipid metabolism is one of the HCV life cycle steps. HCV forms a replication complex in lipid raft membrane that is full of cholesterol and sphingolipids.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="7574" xml_f="7575" txt_i="2639" txt_f="2640">6</offsets></xref><xref rid="ref7" ref-type="bibr"><offsets xml_i="7615" xml_f="7616" txt_i="2640" txt_f="2641">7</offsets></xref><offsets xml_i="7623" xml_f="7825" txt_i="2641" txt_f="2843">] 3-hydroxy-3 methyl-glutaryl Coenzyme A inhibitors (statins) can reduce cholesterol level and finally can decrease HCV replication. Hence, statin therapy can be introduced as a complementary treatment.</offsets></p><p><italic><offsets xml_i="7840" xml_f="7848" txt_i="2844" txt_f="2852">In vitro</offsets></italic><offsets xml_i="7857" xml_f="7970" txt_i="2852" txt_f="2965"> examinations have found that some statins, especially fluvastatin and atorvastatin can inhibit HCV replication,[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="8003" xml_f="8004" txt_i="2965" txt_f="2966">8</offsets></xref><offsets xml_i="8011" xml_f="8126" txt_i="2966" txt_f="3081">] although statins should be used with caution in advanced end-stage liver disease because of decompensation risk.[</offsets><xref rid="ref9" ref-type="bibr"><offsets xml_i="8159" xml_f="8160" txt_i="3081" txt_f="3082">9</offsets></xref><offsets xml_i="8167" xml_f="8168" txt_i="3082" txt_f="3083">]</offsets></p><p><offsets xml_i="8175" xml_f="8283" txt_i="3084" txt_f="3192">Recently, beneficial effect of statin use among patients with HCV-related liver disease has been suggested. </offsets><italic><offsets xml_i="8291" xml_f="8299" txt_i="3192" txt_f="3200">In vitro</offsets></italic><offsets xml_i="8308" xml_f="8444" txt_i="3200" txt_f="3336"> studies show that high concentrations of statins disrupt HCV replication through depletion of isoprenoid geranylgeranyl pyrophosphate.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="8478" xml_f="8480" txt_i="3336" txt_f="3338">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="8521" xml_f="8523" txt_i="3338" txt_f="3340">11</offsets></xref><offsets xml_i="8530" xml_f="8624" txt_i="3340" txt_f="3434">] Statins may thus have antiviral effects through mechanisms not related to lipid metabolism.[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="8658" xml_f="8660" txt_i="3434" txt_f="3436">12</offsets></xref><xref rid="ref13" ref-type="bibr"><offsets xml_i="8701" xml_f="8703" txt_i="3436" txt_f="3438">13</offsets></xref><offsets xml_i="8710" xml_f="9160" txt_i="3438" txt_f="3888">] The low-density lipoprotein (LDL) receptor and the high-density lipoprotein scavenger receptor B1 putatively facilitate HCV entry into hepatocytes. Complex host proteins are found to be closely associated with HCV nonstructural proteins. The process which links these host and HCV proteins is termed prenylation. Statin agents which block the formation of the lipid precursors for prenylation, could theoretically interfere with viral replication.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="9194" xml_f="9196" txt_i="3888" txt_f="3890">14</offsets></xref><xref rid="ref15" ref-type="bibr"><offsets xml_i="9237" xml_f="9239" txt_i="3890" txt_f="3892">15</offsets></xref><xref rid="ref16" ref-type="bibr"><offsets xml_i="9280" xml_f="9282" txt_i="3892" txt_f="3894">16</offsets></xref><offsets xml_i="9289" xml_f="9290" txt_i="3894" txt_f="3895">]</offsets></p><p><offsets xml_i="9297" xml_f="9429" txt_i="3896" txt_f="4028">Some human studies have done for assessing the effect of statins in hepatitis c treatment, but their results are different. O’Leary </offsets><italic><offsets xml_i="9437" xml_f="9442" txt_i="4028" txt_f="4033">et al</offsets></italic><offsets xml_i="9451" xml_f="9539" txt_i="4033" txt_f="4121">. have shown no reduction in HCV-ribonucleic acid (RNA) titers with 20 mg atorvastatin.[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="9573" xml_f="9575" txt_i="4121" txt_f="4123">17</offsets></xref><offsets xml_i="9582" xml_f="9678" txt_i="4123" txt_f="4219">] However, another study indicates non-dose-dependent discretion in HCV-RNA in %50 of patients,[</offsets><xref rid="ref18" ref-type="bibr"><offsets xml_i="9712" xml_f="9714" txt_i="4219" txt_f="4221">18</offsets></xref><offsets xml_i="9721" xml_f="9878" txt_i="4221" txt_f="4378">] the purpose of this study was to determine the effect of statin therapy on standard antiviral treatment response in hyperlipidemic genotype I HCV patients.</offsets></p></sec><sec sec-type="materials|methods" id="sec1-2"><title><offsets xml_i="9941" xml_f="9962" txt_i="4380" txt_f="4401">MATERIALS AND METHODS</offsets></title><sec id="sec2-1"><title><offsets xml_i="9994" xml_f="10021" txt_i="4402" txt_f="4429">Selection of patient groups</offsets></title><p><offsets xml_i="10032" xml_f="10964" txt_i="4430" txt_f="5362">Our study was a prospective clinical trial which was done on genotype I HCV patients who had been referred to educational and therapeutic centers of Isfahan University of Medical Sciences between years 2009 and 2010. All patients were tested to confirm HCV viremia by Cobas Amplicor HCV Monitor test, version 2 (Roche Diagnostics, Mannheim, Germany). We selected our patients using simple random sampling. Subjects in the statin group were hyperlipidemic patients according to WHO definition for hyperlipidemia which is LDL cholesterol level more than 160 mg/dl, 130 mg/dl for patient with one risk factor and 100 mg/dl for patients with diabetes mellitus, 2 or more than risk factors. Patients in the placebo group were selected from HCV patients without hyperlipidemia. This study protocol was approved by Institutional Review Board and Ethics Committee of Isfahan University of Medical Sciences (research project number: 309079).</offsets></p><p><offsets xml_i="10971" xml_f="12095" txt_i="5363" txt_f="6484">Patients were included in the study if they were naïve for HCV treatment, more than 18 years old and patients who did not have any clinical sign for decompensate Cirrhosis. All cases who were affected by other genotypes of HCV and chronic liver disease such as hepatitis B virus, HIV, Wilson disease, hemochromathosis, autoimmune liver disease, primary biliary cirrhosis, secondary biliary cirrhosis, obstructive liver disease, viral infections that affect liver function, and who had the history of alcohol drinking and drugs related steatosis and hepatotoxicity were excluded from our study. Patients were excluded from the study if the level of their liver enzymes (alanine transaminase and aspartate aminotransferase) had risen &gt;3 times during statin treatment. Patients were examined clinically before antiviral treatment. Fasting blood sugar, plasma lipids, liver enzymes tests and liver and abdomen sonography (Hitachi, Tokyo Japan) were done 2 times (with 1 month apart) before treatment for all of them. We also checked their blood pressure, waist size, and body mass index (BMI) according to related guideline.[</offsets><xref rid="ref19" ref-type="bibr"><offsets xml_i="12129" xml_f="12131" txt_i="6484" txt_f="6486">19</offsets></xref><offsets xml_i="12138" xml_f="12688" txt_i="6486" txt_f="7033">] All patients weekly received 180 μg Peg-IFN-a2a and 1000, 1200 and 1400 mg RBV for weights &lt;75 kg, 75-100 kg, and more than 100 kg, respectively (Pegasys Co.). Statin group received 20 mg atorvastatin (Farabi Co., Tehran, Iran) nightly for 3 months and placebo was prescribed for the placebo group the same as atorvastatin in the statin group. Liver enzymes and complete blood count were checked monthly and thyroid stimulating hormone checked every 3 months. We also did quantitative HCV-RNA test to reveal patients with undetectable test in 12</offsets><sup><offsets xml_i="12693" xml_f="12695" txt_i="7033" txt_f="7035">th</offsets></sup><offsets xml_i="12701" xml_f="12855" txt_i="7035" txt_f="7189"> week of therapy (early virological response [EVR]), after therapy (end of treatment virological response) and 6 months after therapy SVR for all samples.</offsets></p><p><offsets xml_i="12862" xml_f="12945" txt_i="7190" txt_f="7273">We analyzed our data using SPSS version 16 (Inc., Chicago, IL, USA) and considered </offsets><italic><offsets xml_i="12953" xml_f="12954" txt_i="7273" txt_f="7274">P</offsets></italic><offsets xml_i="12963" xml_f="13065" txt_i="7274" txt_f="7373"> &lt; 0.05 as valuable, Chi-square was applied for comparison of categorical parameters and Student's </offsets><italic><offsets xml_i="13073" xml_f="13074" txt_i="7373" txt_f="7374">t</offsets></italic><offsets xml_i="13083" xml_f="13129" txt_i="7374" txt_f="7420">-test for comparing the continuous parameters.</offsets></p></sec></sec><sec id="sec1-3"><title><offsets xml_i="13169" xml_f="13175" txt_i="7423" txt_f="7429">RESULT</offsets></title><p><offsets xml_i="13186" xml_f="13430" txt_i="7430" txt_f="7674">Our study included 40 HCV positive patients (20 hyperlipidemic and 20 normolipidemic patients). Our results showed that there are significant differences in the mean of BMI, triglyceride, LDL, and cholesterol between statin and placebo groups [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="13462" xml_f="13469" txt_i="7674" txt_f="7681">Table 1</offsets></xref><offsets xml_i="13476" xml_f="13478" txt_i="7681" txt_f="7683">].</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="13526" xml_f="13533" txt_i="7684" txt_f="7691">Table 1</offsets></label><caption><p><offsets xml_i="13553" xml_f="13612" txt_i="7691" txt_f="7750">demographic and lipid character in statin and placebo group</offsets></p></caption><graphic xlink:href="JRMS-19-1-g001"></graphic></table-wrap><p><offsets xml_i="13689" xml_f="13920" txt_i="7751" txt_f="7982">The evaluation of viral load before statin therapy did not show a significant difference between statin and placebo, also, we didn't find any significant differences in the mean of HCV-RNA numbers in statin and placebo groups in 12</offsets><sup><offsets xml_i="13925" xml_f="13927" txt_i="7982" txt_f="7984">th</offsets></sup><offsets xml_i="13933" xml_f="13959" txt_i="7984" txt_f="8010"> week of Statins therapy (</offsets><italic><offsets xml_i="13967" xml_f="13968" txt_i="8010" txt_f="8011">P</offsets></italic><offsets xml_i="13977" xml_f="14015" txt_i="8011" txt_f="8046"> &gt; 0.05), at the end of treatment (</offsets><italic><offsets xml_i="14023" xml_f="14024" txt_i="8046" txt_f="8047">P</offsets></italic><offsets xml_i="14033" xml_f="14075" txt_i="8047" txt_f="8086"> &gt; 0.05) and 6 months after treatment (</offsets><italic><offsets xml_i="14083" xml_f="14084" txt_i="8086" txt_f="8087">P</offsets></italic><offsets xml_i="14093" xml_f="14106" txt_i="8087" txt_f="8097"> &gt; 0.05) [</offsets><xref ref-type="table" rid="T2"><offsets xml_i="14138" xml_f="14145" txt_i="8097" txt_f="8104">Table 2</offsets></xref><offsets xml_i="14152" xml_f="14315" txt_i="8104" txt_f="8267">]. Our findings also implied that EVR in statin and placebo were 75 and 70% and SVR was 95% in both groups. ALT level was higher in statin group before treatment [</offsets><xref ref-type="table" rid="T3"><offsets xml_i="14347" xml_f="14354" txt_i="8267" txt_f="8274">Table 3</offsets></xref><offsets xml_i="14361" xml_f="14491" txt_i="8274" txt_f="8404">]. Although both AST and ALT level rose after treatment, we did not find any difference between AST and ALT level after treatment.</offsets></p><table-wrap id="T2" position="float"><label><offsets xml_i="14539" xml_f="14546" txt_i="8405" txt_f="8412">Table 2</offsets></label><caption><p><offsets xml_i="14566" xml_f="14675" txt_i="8412" txt_f="8521">Comparison between viral load before treatment and after start of treatment between statin and placebo groups</offsets></p></caption><graphic xlink:href="JRMS-19-1-g002"></graphic></table-wrap><table-wrap id="T3" position="float"><label><offsets xml_i="14793" xml_f="14800" txt_i="8522" txt_f="8529">Table 3</offsets></label><caption><p><offsets xml_i="14820" xml_f="14907" txt_i="8529" txt_f="8616">comparison between transaminases in statin and placebo group before and after treatment</offsets></p></caption><graphic xlink:href="JRMS-19-1-g003"></graphic></table-wrap></sec><sec sec-type="discussion" id="sec1-4"><title><offsets xml_i="15033" xml_f="15043" txt_i="8618" txt_f="8628">DISCUSSION</offsets></title><p><offsets xml_i="15054" xml_f="15194" txt_i="8629" txt_f="8769">In the current study, we didn't find any significant differences in the mean of viral load of hepatitis c in statin and placebo groups in 12</offsets><sup><offsets xml_i="15199" xml_f="15201" txt_i="8769" txt_f="8771">th</offsets></sup><offsets xml_i="15207" xml_f="15474" txt_i="8771" txt_f="9038"> week of statin therapy, at the end of treatment and 6 months after treatment. Our findings also implied that early response to treatment (EVR) in statin and placebo were 70 and 75% and Sustain response to treatment (SVR) in statin and placebo was 95% in both groups.</offsets></p><p><offsets xml_i="15481" xml_f="15671" txt_i="9039" txt_f="9229">A pilot study of 31 HCV-infected veterans who were given fluvastatin 20-320 mg/day for 2-12 weeks with weekly monitoring of HCV-RNA and liver tests reported modest reductions of viral load.[</offsets><xref rid="ref20" ref-type="bibr"><offsets xml_i="15705" xml_f="15707" txt_i="9229" txt_f="9231">20</offsets></xref><offsets xml_i="15714" xml_f="15927" txt_i="9231" txt_f="9444">] Furthermore, a pharmacoepidemiologic study found that the use of lovastatin was associated with a 40-50% lower incidence of moderate as well as severe liver injury among patients with preexisting liver disease.[</offsets><xref rid="ref21" ref-type="bibr"><offsets xml_i="15961" xml_f="15963" txt_i="9444" txt_f="9446">21</offsets></xref><offsets xml_i="15970" xml_f="15971" txt_i="9446" txt_f="9447">]</offsets></p><p><offsets xml_i="15978" xml_f="16391" txt_i="9448" txt_f="9861">Even though, prior individual studies examined important aspects of the association between statin and lowering the severity if liver disease in HCV-infected patients, these studies either did not adjust for histological severity of liver disease, had generally short follow-up, or did not use placebo subjects. Clearly, more information is needed about the possible beneficial effect of statins in HCV-infected.[</offsets><xref rid="ref22" ref-type="bibr"><offsets xml_i="16425" xml_f="16427" txt_i="9861" txt_f="9863">22</offsets></xref><offsets xml_i="16434" xml_f="16435" txt_i="9863" txt_f="9864">]</offsets></p><p><offsets xml_i="16442" xml_f="16462" txt_i="9865" txt_f="9885">The result of other </offsets><italic><offsets xml_i="16470" xml_f="16477" txt_i="9885" txt_f="9892">in vivo</offsets></italic><offsets xml_i="16486" xml_f="16574" txt_i="9892" txt_f="9980"> studies has been same as our findings in this study. A study which has done by O’Leary </offsets><italic><offsets xml_i="16582" xml_f="16587" txt_i="9980" txt_f="9985">et al</offsets></italic><offsets xml_i="16596" xml_f="16679" txt_i="9985" txt_f="10068">. (2007) on 10 samples show that atorvastatin does not inhibit HCV-RNA replication </offsets><italic><offsets xml_i="16687" xml_f="16694" txt_i="10068" txt_f="10075">in vivo</offsets></italic><offsets xml_i="16703" xml_f="16705" txt_i="10075" txt_f="10077">.[</offsets><xref rid="ref17" ref-type="bibr"><offsets xml_i="16739" xml_f="16741" txt_i="10077" txt_f="10079">17</offsets></xref><offsets xml_i="16748" xml_f="16756" txt_i="10079" txt_f="10087">] Forde </offsets><italic><offsets xml_i="16764" xml_f="16769" txt_i="10087" txt_f="10092">et al</offsets></italic><offsets xml_i="16778" xml_f="16891" txt_i="10092" txt_f="10205">. in a cross-sectional study (2009) confirmed that statins don't have any apparent effect on HCV-RNA replication </offsets><italic><offsets xml_i="16899" xml_f="16906" txt_i="10205" txt_f="10212">in vivo</offsets></italic><offsets xml_i="16915" xml_f="16917" txt_i="10212" txt_f="10214">.[</offsets><xref rid="ref23" ref-type="bibr"><offsets xml_i="16951" xml_f="16953" txt_i="10214" txt_f="10216">23</offsets></xref><offsets xml_i="16960" xml_f="16961" txt_i="10216" txt_f="10217">]</offsets></p><p><offsets xml_i="16968" xml_f="16975" txt_i="10218" txt_f="10225">Unlike </offsets><italic><offsets xml_i="16983" xml_f="16990" txt_i="10225" txt_f="10232">in vivo</offsets></italic><offsets xml_i="16999" xml_f="17022" txt_i="10232" txt_f="10255"> studies the result of </offsets><italic><offsets xml_i="17030" xml_f="17038" txt_i="10255" txt_f="10263">in vitro</offsets></italic><offsets xml_i="17047" xml_f="17114" txt_i="10263" txt_f="10330"> research has shown that statins can decrease HCV-RNA replication.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="17147" xml_f="17148" txt_i="10330" txt_f="10331">3</offsets></xref><offsets xml_i="17155" xml_f="17163" txt_i="10331" txt_f="10339">] Ikeda </offsets><italic><offsets xml_i="17171" xml_f="17176" txt_i="10339" txt_f="10344">et al</offsets></italic><offsets xml_i="17185" xml_f="17256" txt_i="10344" txt_f="10415">. evaluated the effect of statins on HCV-RNA replication in OR6 cells.[</offsets><xref rid="ref24" ref-type="bibr"><offsets xml_i="17290" xml_f="17292" txt_i="10415" txt_f="10417">24</offsets></xref><offsets xml_i="17299" xml_f="17525" txt_i="10417" txt_f="10643">] Fluvastatin exhibited the strongest anti-HCV activity while atorvastatin and simvastatin showed moderate inhibitory effects. The combination of IFN and the statins exhibited strong inhibitory effects on HCV-RNA replication.[</offsets><xref rid="ref25" ref-type="bibr"><offsets xml_i="17559" xml_f="17561" txt_i="10643" txt_f="10645">25</offsets></xref><xref rid="ref26" ref-type="bibr"><offsets xml_i="17602" xml_f="17604" txt_i="10645" txt_f="10647">26</offsets></xref><offsets xml_i="17611" xml_f="17612" txt_i="10647" txt_f="10648">]</offsets></p><p><offsets xml_i="17619" xml_f="17666" txt_i="10649" txt_f="10696">There are some reasons for differences between </offsets><italic><offsets xml_i="17674" xml_f="17682" txt_i="10696" txt_f="10704">in vitro</offsets></italic><offsets xml_i="17691" xml_f="17696" txt_i="10704" txt_f="10709"> and </offsets><italic><offsets xml_i="17704" xml_f="17711" txt_i="10709" txt_f="10716">in vivo</offsets></italic><offsets xml_i="17720" xml_f="17877" txt_i="10716" txt_f="10873"> studies. As we told before various factors affect on antiviral treatment response in the human body such as obesity, insulin resistance and liver steatosis[</offsets><xref rid="ref15" ref-type="bibr"><offsets xml_i="17911" xml_f="17913" txt_i="10873" txt_f="10875">15</offsets></xref><xref rid="ref16" ref-type="bibr"><offsets xml_i="17954" xml_f="17956" txt_i="10875" txt_f="10877">16</offsets></xref><offsets xml_i="17963" xml_f="18342" txt_i="10877" txt_f="11256">] so we need to do more studies to examine the effect of statins on HCV in relation to confounder factors. On the other hand, statins concentration in cell cultures is higher than their concentration in plasma. Studies have shown that serum levels of such agents after prolonged therapy are significantly lower than the statin concentrations those were used in replicon systems.[</offsets><xref rid="ref27" ref-type="bibr"><offsets xml_i="18376" xml_f="18378" txt_i="11256" txt_f="11258">27</offsets></xref><offsets xml_i="18385" xml_f="18386" txt_i="11258" txt_f="11259">]</offsets></p><p><offsets xml_i="18393" xml_f="18640" txt_i="11260" txt_f="11507">In our study, response rate of patients were higher than western studies, there are some similar reports that show high response rate of combination therapy in Iranian patients, it may be due to lower viral load in comparison to western patients.[</offsets><xref rid="ref28" ref-type="bibr"><offsets xml_i="18674" xml_f="18676" txt_i="11507" txt_f="11509">28</offsets></xref><xref rid="ref29" ref-type="bibr"><offsets xml_i="18717" xml_f="18719" txt_i="11509" txt_f="11511">29</offsets></xref><offsets xml_i="18726" xml_f="18727" txt_i="11511" txt_f="11512">]</offsets></p><p><offsets xml_i="18734" xml_f="19047" txt_i="11513" txt_f="11826">In summary in our study statins did not have any significant effect on HCV virus number and virologic response. Our limitation in this study was few sample size, and further studies are necessary to examine the possible antiviral properties of statins and their potential role as adjuncts to standard HCV therapy.</offsets></p></sec><sec id="sec1-5"><title><offsets xml_i="19081" xml_f="19102" txt_i="11828" txt_f="11849">AUTHORS’ CONTRIBUTION</offsets></title><p><offsets xml_i="19113" xml_f="19526" txt_i="11850" txt_f="12263">All authors have contributed in designing and conducting the study. Ash, AB, SS, SSh, and Nkh collected the data and MM, MKh, MT, Ash, and BA did the analysis. All authors have assisted in preparation of the first draft of the manuscript or revising it critically for important intellectual content. All authors have read and approved the content of the manuscript and are accountable for all aspects of the work.</offsets></p></sec></body><back><ack><title>ACKNOWLEDGMENT</title><p>Authors are grateful to Professor Mohsen Janghorbani for his valuable comments on the manuscript.</p></ack><fn-group><fn fn-type="supported-by"><p><bold>Source of Support:</bold> Nil</p></fn><fn fn-type="conflict"><p><bold>Conflict of Interest:</bold> The authors have no conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Serag</surname><given-names>HB</given-names></name><name><surname>Mason</surname><given-names>AC</given-names></name></person-group><article-title>Rising incidence of hepatocellular carcinoma in the United States</article-title><source>N Engl J Med</source><year>1999</year><volume>340</volume><fpage>745</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">10072408</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>GL</given-names></name><name><surname>Albright</surname><given-names>JE</given-names></name><name><surname>Cook</surname><given-names>SF</given-names></name><name><surname>Rosenberg</surname><given-names>DM</given-names></name></person-group><article-title>Projecting future complications of chronic hepatitis C in the United States</article-title><source>Liver Transpl</source><year>2003</year><volume>9</volume><fpage>331</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">12682882</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>N</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>P</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><etal></etal></person-group><article-title>Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: A systematic review and meta-analysis</article-title><source>Antiviral Res</source><year>2013</year><volume>98</volume><fpage>373</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23603497</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vere</surname><given-names>CC</given-names></name><name><surname>Streba</surname><given-names>CT</given-names></name><name><surname>Streba</surname><given-names>L</given-names></name><name><surname>Rogoveanu</surname><given-names>I</given-names></name></person-group><article-title>Statins in the treatment of hepatitis C</article-title><source>Hepat Mon</source><year>2012</year><volume>12</volume><fpage>369</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">22879825</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blanchet</surname><given-names>M</given-names></name><name><surname>Seidah</surname><given-names>NG</given-names></name><name><surname>Labonté</surname><given-names>P</given-names></name></person-group><article-title>SKI-1/S1P inhibition: A promising surrogate to statins to block hepatitis C virus replication</article-title><source>Antiviral Res</source><year>2012</year><volume>95</volume><fpage>159</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">22626636</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SS</given-names></name><name><surname>Peng</surname><given-names>LF</given-names></name><name><surname>Lin</surname><given-names>W</given-names></name><name><surname>Choe</surname><given-names>WH</given-names></name><name><surname>Sakamoto</surname><given-names>N</given-names></name><name><surname>Kato</surname><given-names>N</given-names></name><etal></etal></person-group><article-title>A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication</article-title><source>Gastroenterology</source><year>2007</year><volume>132</volume><fpage>311</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">17241881</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Kato</surname><given-names>N</given-names></name></person-group><article-title>Life style-related diseases of the digestive system: Cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: Suppression of HCV replication by statins and synergistic action with interferon</article-title><source>J Pharmacol Sci</source><year>2007</year><volume>105</volume><fpage>145</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17928739</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>van Heeswijk</surname><given-names>R</given-names></name><name><surname>Alves</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>F</given-names></name><name><surname>Garg</surname><given-names>V</given-names></name></person-group><article-title>Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin</article-title><source>Antimicrob Agents Chemother</source><year>2011</year><volume>55</volume><fpage>4569</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">21825288</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrus</surname><given-names>MR</given-names></name><name><surname>East</surname><given-names>J</given-names></name></person-group><article-title>Use of statins in patients with chronic hepatitis C</article-title><source>South Med J</source><year>2010</year><volume>103</volume><fpage>1018</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">20818300</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lonardo</surname><given-names>A</given-names></name><name><surname>Loria</surname><given-names>P</given-names></name><name><surname>Carulli</surname><given-names>N</given-names></name></person-group><article-title>Dysmetabolic changes associated with HCV: A distinct syndrome?</article-title><source>Intern Emerg Med</source><year>2008</year><volume>3</volume><fpage>99</fpage><lpage>108</lpage><pub-id pub-id-type="pmid">18274709</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conjeevaram</surname><given-names>HS</given-names></name><name><surname>Kleiner</surname><given-names>DE</given-names></name><name><surname>Everhart</surname><given-names>JE</given-names></name><name><surname>Hoofnagle</surname><given-names>JH</given-names></name><name><surname>Zacks</surname><given-names>S</given-names></name><name><surname>Afdhal</surname><given-names>NH</given-names></name><etal></etal></person-group><article-title>Race, insulin resistance and hepatic steatosis in chronic hepatitis C</article-title><source>Hepatology</source><year>2007</year><volume>45</volume><fpage>80</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17187406</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rubbia-Brandt</surname><given-names>L</given-names></name><name><surname>Quadri</surname><given-names>R</given-names></name><name><surname>Abid</surname><given-names>K</given-names></name><name><surname>Giostra</surname><given-names>E</given-names></name><name><surname>Malé</surname><given-names>PJ</given-names></name><name><surname>Mentha</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3</article-title><source>J Hepatol</source><year>2000</year><volume>33</volume><fpage>106</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">10905593</pub-id></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patton</surname><given-names>HM</given-names></name><name><surname>Patel</surname><given-names>K</given-names></name><name><surname>Behling</surname><given-names>C</given-names></name><name><surname>Bylund</surname><given-names>D</given-names></name><name><surname>Blatt</surname><given-names>LM</given-names></name><name><surname>Vallée</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients</article-title><source>J Hepatol</source><year>2004</year><volume>40</volume><fpage>484</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">15123364</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fartoux</surname><given-names>L</given-names></name><name><surname>Poujol-Robert</surname><given-names>A</given-names></name><name><surname>Guéchot</surname><given-names>J</given-names></name><name><surname>Wendum</surname><given-names>D</given-names></name><name><surname>Poupon</surname><given-names>R</given-names></name><name><surname>Serfaty</surname><given-names>L</given-names></name></person-group><article-title>Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C</article-title><source>Gut</source><year>2005</year><volume>54</volume><fpage>1003</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">15951550</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adinolfi</surname><given-names>LE</given-names></name><name><surname>Durante-Mangoni</surname><given-names>E</given-names></name><name><surname>Zampino</surname><given-names>R</given-names></name><name><surname>Ruggiero</surname><given-names>G</given-names></name></person-group><article-title>Review article: Hepatitis C virus-associated steatosis – Pathogenic mechanisms and clinical implications</article-title><source>Aliment Pharmacol Ther</source><year>2005</year><volume>22</volume><issue>Suppl 2</issue><fpage>52</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16225474</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lecube</surname><given-names>A</given-names></name><name><surname>Hernández</surname><given-names>C</given-names></name><name><surname>Simó</surname><given-names>R</given-names></name><name><surname>Esteban</surname><given-names>JI</given-names></name><name><surname>Genescà</surname><given-names>J</given-names></name></person-group><article-title>Glucose abnormalities are an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C</article-title><source>Am J Gastroenterol</source><year>2007</year><volume>102</volume><fpage>2189</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">17617205</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Leary</surname><given-names>JG</given-names></name><name><surname>Chan</surname><given-names>JL</given-names></name><name><surname>McMahon</surname><given-names>CM</given-names></name><name><surname>Chung</surname><given-names>RT</given-names></name></person-group><article-title>Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: A pilot clinical trial</article-title><source>Hepatology</source><year>2007</year><volume>45</volume><fpage>895</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17393518</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bader</surname><given-names>T</given-names></name><name><surname>Fazili</surname><given-names>J</given-names></name><name><surname>Madhoun</surname><given-names>M</given-names></name><name><surname>Aston</surname><given-names>C</given-names></name><name><surname>Hughes</surname><given-names>D</given-names></name><name><surname>Rizvi</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Fluvastatin inhibits hepatitis C replication in humans</article-title><source>Am J Gastroenterol</source><year>2008</year><volume>103</volume><fpage>1383</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18410471</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Cleeman</surname><given-names>JI</given-names></name><name><surname>Daniels</surname><given-names>SR</given-names></name><name><surname>Donato</surname><given-names>KA</given-names></name><name><surname>Eckel</surname><given-names>RH</given-names></name><name><surname>Franklin</surname><given-names>BA</given-names></name><etal></etal></person-group><article-title>Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement</article-title><source>Circulation</source><year>2005</year><volume>112</volume><fpage>2735</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">16157765</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>JM</given-names></name><name><surname>Sud</surname><given-names>A</given-names></name><name><surname>Farrell</surname><given-names>GC</given-names></name><name><surname>Bandara</surname><given-names>P</given-names></name><name><surname>Byth</surname><given-names>K</given-names></name><name><surname>Kench</surname><given-names>JG</given-names></name><etal></etal></person-group><article-title>Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]</article-title><source>Gastroenterology</source><year>2003</year><volume>125</volume><fpage>1695</fpage><lpage>704</lpage><pub-id pub-id-type="pmid">14724822</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ramesh</surname><given-names>S</given-names></name><name><surname>Sanyal</surname><given-names>AJ</given-names></name></person-group><article-title>Hepatitis C and nonalcoholic fatty liver disease</article-title><source>Semin Liver Dis</source><year>2004</year><volume>24</volume><fpage>399</fpage><lpage>413</lpage><pub-id pub-id-type="pmid">15605308</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maillard</surname><given-names>P</given-names></name><name><surname>Krawczynski</surname><given-names>K</given-names></name><name><surname>Nitkiewicz</surname><given-names>J</given-names></name><name><surname>Bronnert</surname><given-names>C</given-names></name><name><surname>Sidorkiewicz</surname><given-names>M</given-names></name><name><surname>Gounon</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Nonenveloped nucleocapsids of hepatitis C virus in the serum of infected patients</article-title><source>J Virol</source><year>2001</year><volume>75</volume><fpage>8240</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">11483769</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Forde</surname><given-names>KA</given-names></name><name><surname>Law</surname><given-names>C</given-names></name><name><surname>O’Flynn</surname><given-names>R</given-names></name><name><surname>Kaplan</surname><given-names>DE</given-names></name></person-group><article-title>Do statins reduce hepatitis C RNA titers during routine clinical use?</article-title><source>World J Gastroenterol</source><year>2009</year><volume>15</volume><fpage>5020</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">19859994</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikeda</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Dansako</surname><given-names>H</given-names></name><name><surname>Naka</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>N</given-names></name></person-group><article-title>Different anti-HCV profiles of statins and their potential for combination therapy with interferon</article-title><source>Hepatology</source><year>2006</year><volume>44</volume><fpage>117</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">16799963</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fried</surname><given-names>MW</given-names></name><name><surname>Shiffman</surname><given-names>ML</given-names></name><name><surname>Reddy</surname><given-names>KR</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Marinos</surname><given-names>G</given-names></name><name><surname>Gonçales</surname><given-names>FL</given-names><suffix>Jr</suffix></name><etal></etal></person-group><article-title>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection</article-title><source>N Engl J Med</source><year>2002</year><volume>347</volume><fpage>975</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">12324553</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vere</surname><given-names>CC</given-names></name><name><surname>Streba</surname><given-names>CT</given-names></name><name><surname>Streba</surname><given-names>L</given-names></name><name><surname>Rogoveanu</surname><given-names>I</given-names></name></person-group><article-title>Statins in the Treatment of Hepatitis C</article-title><source>Hepatitis Monthly</source><year>2012</year><volume>12</volume><fpage>369</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">22879825</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hui</surname><given-names>JM</given-names></name><name><surname>Kench</surname><given-names>J</given-names></name><name><surname>Farrell</surname><given-names>GC</given-names></name><name><surname>Lin</surname><given-names>R</given-names></name><name><surname>Samarasinghe</surname><given-names>D</given-names></name><name><surname>Liddle</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection</article-title><source>J Gastroenterol Hepatol</source><year>2002</year><volume>17</volume><fpage>873</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">12164963</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alavi</surname><given-names>Moghaddam M</given-names></name><name><surname>Zali</surname><given-names>MR</given-names></name><name><surname>Aalaei</surname><given-names>Andabili SH</given-names></name><name><surname>Derakhshan</surname><given-names>F</given-names></name><name><surname>Miri</surname><given-names>SM</given-names></name><name><surname>Alavian</surname><given-names>SM</given-names></name></person-group><article-title>High rate of virological response to peginterferon α-2a-ribavirin among non-cirrhotic Iranian hemophilia patients with chronic hepatitis C</article-title><source>Iran Red Crescent Med J</source><year>2012</year><volume>14</volume><fpage>466</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23105981</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alavian</surname><given-names>SM</given-names></name><name><surname>Behnava</surname><given-names>B</given-names></name><name><surname>Tabatabaei</surname><given-names>SV</given-names></name></person-group><article-title>The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: A meta-analysis</article-title><source>Hepat Mon</source><year>2010</year><volume>10</volume><fpage>121</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">22312385</pub-id></element-citation></ref></ref-list></back></article>